Pfizer to present new cancer data at ASCO 2012

Pfizer will be attending the forthcoming 2012 American Society of Clinical Oncology (ASCO) annual meeting in order to present data on a wide variety of cancer therapies.

The company will travel to Chicago at the beginning of next month to present approximately 100 abstracts pertaining to cancer treatments and investigational compounds spanning 20 cancer types.

Attention will focus on three key therapeutic categories – kidney cancer, lung tumours and haematologic malignancies – with featured therapies including the likes of Inlyta, Sutent, Xalkori, dacomitinib and bosutinib.

These drugs have been developed in collaboration with academia, cooperative groups and patient advocacy groups, reflecting Pfizer's current approach to product development.

Dr Mace Rothenberg, senior vice-president of clinical development and medical affairs for Pfizer's oncology business unit, said: "This data demonstrates Pfizer Oncology's commitment to accelerating the science of therapeutic innovation in some of the most challenging cancers."

Last month, Pfizer was granted UK approval for its drug Inspra to be used in a new specification among chronic heart failure patients.